Sphingosine-1-phosphate (S1P) is a bioactive lipid that binds to S1P receptor subtypes (S1PR1-5) to mediate cellular activities of the immune, cardiovascular and nervous systems.51 S1PR2 is an emerging drug target in multiple sclerosis52, which was the primary indication used for fingolimod in the MR, due to its implication in CNS demyelination. The gene discussed is S1PR2; the disease is miotic rate.